Author: Jansen Tim L Mulder CJJ
Publisher: Informa Healthcare
ISSN: 1471-2598
Source: Expert Opinion on Biological Therapy, Vol.12, Iss.4, 2012-04, pp. : 391-393
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Effective and less toxic biologics have revolutionized rheumatology as well as hepatology over the last decennia resulting in higher therapeutic goals. Traditional disease modifying anti-rheumatic drugs (tDMARDs) failing to achieve a quiescent chronic rheumatoid arthritis (RA) or spondylarthropathic arthritis (SA) inflammatory disease, nowadays are to be switched into a more potent strategy with ultimately a combination of tDMARD plus TNF inhibitors (TNFi) early in disease. Patients with previous microbiological infections however present a challenge for a modern rheumatologist aiming at complete remission, particularly in carriers of viral infections. Hepatologists nowadays, can treat chronic hepatitis B and C virus infections effectively with potent antivirals. In the current issue an overview is given regarding patients in whom TNFi may be indicated, but also have been infected with viral hepatitis.
Related content
By Beaulieu P.L. Bos M. Bousquet Y. DeRoy P. Fazal G. Gauthier J. Gillard J. Goulet S. McKercher G. Poupart M.-A. Valois S. Kukolj G.
Bioorganic and Medicinal Chemistry Letters, Vol. 14, Iss. 4, 2004-02 ,pp. :
By Wen J.-K. Zhang X.-E. Cheng Z. Liu H. Zhou Y.-F. Zhang Z.-P. Yang J.-H. Deng J.-Y.
Biosensors and Bioelectronics, Vol. 19, Iss. 7, 2004-02 ,pp. :
By Cho Min-Hyung Song Jin-Su Kim Hie-Joon Park Sung-Gyoo Jung Guhung
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 28, Iss. 5, 2013-10 ,pp. :